Capsida Biotherapeutics

Eli Lilly Turns to Startup Capsida to Bring Gene Therapy Into the Brain

Eli Lilly is paying $55 million up front to begin an alliance with Capsida Biotherapeutics pursuing gene therapies for central nervous system disorders. Capsida’s technology enables the delivery of a gene therapy to a single organ or multiple organs, a capability that could bring such treatments to a wider range of diseases.

By Frank Vinluan

BioPharma, Startups

Capsida unveils $140M, AbbVie alliance & tech that takes gene therapy to the brain

Capsida Biotherapeutics’ technology can engineer viral vectors that deliver gene therapies to central nervous system cells. With that capability, the startup was able to raise $50 million in Series A financing and a multi-drug research alliance AbbVie.

By Frank Vinluan